Advisory Committees: FDA Gets Out Of The Redaction Business
This article was originally published in The Rose Sheet
Executive Summary
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.
You may also be interested in...
US FDA May Change Advisory Committee Planning, Member Screening
Departing Commissioner says that special government employee procedure especially is in need of reform.
FDA Advisory Committee Disclosures Sought In Public Citizen Suit
Unredacted curricula vitae could disclose privately funded grants, pending clinical trials, and pending publications among other information.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.